Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
The Phase I study, led by a researcher at NYU Langone Health and its Perlmutter Cancer Center, is also among the first to show how such oncolytic viruses can safely boost the action of widely used cancer therapies that help the body’s immune defense system detect and kill cancer cells. Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
The new study results showed that injections of experimental coxsackievirus drug V937, along with pembrolizumab, an immunotherapy drug known as pembro or Keytruda, was well tolerated. Moreover, the combined treatment shrank melanoma tumors in nearly half (47 percent) of 36 men and women who received the therapy every few weeks for at least two years.
Researchers say most side effects, such as rash and fatigue, were minimal, while 13 patients (36 percent) had serious immune reactions in the liver, stomach, or lungs, not unlike side effects that are known to happen with pembrolizumab alone.
Set for presentation at the annual meeting of the American Association for Cancer Research online April 10, the study also showed that eight patients who received both drugs (22 percent) experienced complete remission, with no remaining signs of skin cancer.
“Our initial study results are very promising and show that this oncolytic virus injection, a modified coxsackievirus, when combined with existing immunotherapy is not only safe but has the potential to work better against melanoma than immunotherapy alone,” says study senior investigator and medical oncologist Janice Mehnert, MD.
Mehnert, a professor at NYU Grossman School of Medicine and associate director of clinical research at Perlmutter Cancer Center, cautions that further testing, already underway, would have to prove successful before the combination treatment could become a “standard of care,” or go-to therapy, for patients with advanced melanoma, meaning melanoma that has spread to other parts of the body.
She adds that the next phase of clinical trials will involve patients with melanoma that has become widespread, as well as in patients whose tumors, if shrunken by the drug combination, could be more easily removed by surgery.
Among the study’s other findings was that patients least likely to respond to immunotherapy alone were those who responded best to the combined treatment. Patients, for example, who responded best had less of the chemical receptors (PDL1) on the surfaces of cancer cells that are blocked by pembrolizumab than patients who did not respond as well.
Researchers say further experiments are needed to determine how V937 changes the molecular makeup of the tissues immediately surrounding tumors.
“Our goal is to determine if the virus turns the tumor microenvironment from ‘friendly’ to one that is ‘unfriendly,’ making the cancer cells more vulnerable to pembrolizumab,” says Mehnert.
As part of the latest study, volunteers, mostly seniors, enrolled at three cancer clinics, including Rutgers Cancer Institute in New Brunswick, NJ; Gabrail Cancer Center in Canton, Ohio; and John Wayne Cancer Institute in Santa Monica, Calif.
Scientists have known since the 1800s that some cancer patients who suffered from infections, later tied to bacteria or viruses that cause measles and herpes, often experience tumor shrinkage. Recent technological advances in genetic engineering have allowed scientists to retool viruses to target specific molecules on the surface of cancer cells to more easily infect them.
Funding support for the study, known as CAPRA, was provided by Viralytics, the manufacturer of the V937 drug used in the experiments, and by Merck of Kenilworth, NJ, which owns Viralytics and produces pembrolizumab, the other drug involved in the research. More information about the trial can be found online at https://clinicaltrials.gov/ct2/show/NCT02565992.
Besides Mehnert, other researchers involved in the study are study investigators Ann Silk at Dana-Farber Cancer Institute in Boston; Steven O’Day at John Wayne Cancer Institute in Santa Monica, Calif.; Howard Kaufman at Massachusetts General Hospital in Boston; Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Daniel Medina, and Joshua Vieth at Rutgers University; Seymour Fein at Seattle Cancer Care Alliance; Cai Wu and Leslie Guerreiro at Merck; Andrew Zloza at Rush University in Chicago; Bernard Fox and Carmen Ballesteros-Merino at Providence Portland Medical Center in Ore.; Darren Shafren at ImmVirX in New Lambton Heights, Australia; and Mark Grose at Viralytics in Kenilworth, NJ.